Notice: Trying to get property 'slug' of non-object in /home/sgumdev/public_html/wp-content/themes/sgum_2016/single.php on line 44

written by reader Tremblay’s Prediction of 80,000% Sales Surge for New Antibiotic to Cure Drug-Resistant Pneumonia

By new2options, October 18, 2016

Any ideas on what stock is being pitched by Tremblay at Biotech Insider Alert as the ”biggest breakthrough since penicillin?”

Here are some teaser quotes from the ad:
”It happens November 4 at 8:30 a.m. Urgent FDA Meeting Poised to Ignite 80,000% Sales
Surge for Tiny Company!”
”… could displace the entire $45 billion antibiotic sector”
”… the FDA is preparing a rare DOUBLE-SHOT DECISION that could unleash a new ”Star Wars” treatment, worth a projected $45 billion.”
”… the company’s CEO, CFO, and Executive VP – have snapped up nearly 90% of available shares alongside institutions… a legendary billionaire has just INCREASED his position in this tiny company by a staggering 571%.”
”… the FDA has given it a rare ”FAST-TRACK” designation… this special FDA classification gives the company a dominant five-year monopoly!”

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

4 Comments
Inline Feedbacks
View all comments

Notice: Undefined variable: karmaOutput in /home/sgumdev/public_html/wp-content/themes/sgum_2016/functions.php on line 3288

Notice: Undefined variable: karmaOutput in /home/sgumdev/public_html/wp-content/themes/sgum_2016/functions.php on line 3288
marku
marku
5 years ago

Looking at the clues I think it may be $AKAO.

👍 82
marku
marku
5 years ago

I actually now think it is $CEMP.

It mentions an FDA decision expected by December 27 .. and CEMP has a PDUFA on that date for Solithera – oral Community-acquired bacterial pneumonia (CABP).

The $27 million is not the market cap, it actually says “this company’s sales are a mere $27 million” … to confuse the readers. No position in CEMP.

Add a Topic
3022
Add a Topic
5421
👍 82
jerickson68
jerickson68
5 years ago

So, Cempra Pharmaceutical (CEMP) has a meeting on the 4th. Given the stock action doesn’t look like this huge announcement has been leaked.
http://www.fda.gov/AdvisoryCommittees/Calendar/ucm518797.htm

Add a Topic
5971
Jules
5 years ago

CEMP : It is eight to 16 times more potent than azithromycin against many bacteria and is active against azithromycin-resistant strains. The activity of solithromycin against resistant strains is driven by its ability to interact with three sites on the bacterial ribosome, compared to the single binding site of first and second generation macrolides. Sound familiar: 3-prong attack and 16x’s more potent

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info